Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12779114 | 0.88 | TP53 (0.54) | TP53THRBHRH3LMNAABCB1 | |
| SCHEMBL16026529 | 0.84 | THRB (0.61) | TP53THRBHRH3ABCB1ABCC1 | |
| SCHEMBL29922137 | 0.84 | THRB (0.61) | TP53THRBHRH3ABCB1ABCC1 | |
| SCHEMBL12359541 | 0.82 | THRB (0.56) | TP53THRBHRH3ABCB1ABCC1 | |
| SCHEMBL18390916 | 0.80 | THRB (0.54) | TP53THRBHRH3ABCB1ABCC1 | |
| SCHEMBL868571 | 0.78 | HRH3 (0.56) | TP53THRBHRH3SIGMAR1CYP2D6 | |
| SCHEMBL1305923 | 0.77 | HRH1 (0.59) | TP53THRBHRH3ABCB1ABCC1 | |
| SCHEMBL12427505 | 0.77 | THRB (0.54) | TP53THRBHRH3ABCB1ABCC1 | |
| SCHEMBL20382067 | 0.77 | SLC6A3 (0.58) | SIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL3939455 | 0.77 | HRH3 (0.55) | TP53THRBHRH3SIGMAR1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | TP53 1441/4885THRB 622/4885HRH3 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.